Vertex's diverse pipeline ... Marketing will involve working with hospitals to gain formulary access through the Pharmacy & Therapeutics process. Launch dynamics may show faster uptake in the ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Vertex’s excellent Q3 results demonstrate ... Obviously patients in acute pain can’t wait and so when they turn up at a retail pharmacy with a prescription for susetrogene, that susetrogene ...

The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...

The drug for CF (CFTR modulators), while under monopoly, continues to be unavailable in the country due to a lack of registration by Vertex (the patentee ... manufacturing to play its crucial role as ...

Originating as a pharmacy founded in Darmstadt in 1668 ... over time as more competitors came to market. And firms such as Vertex have added to the controversy with tough pricing demands for ...

One example of such a dispute is over access to Vertex’s cystic fibrosis drug ... Rob Duncombe is director of pharmacy at the Christie in Manchester, one of the country’s leading cancer ...

(Bloomberg) -- Big US pharmacy chains were held up as a sign of progress a ... including health care companies Centene Corp., Elevance Health Inc. and Vertex Pharmaceuticals Inc. and animal health ...

Vertex Pharmaceuticals Incorporated ... Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.

But that doesn’t make them all good candidate for one of the two FDA-approved gene therapies for sickle cell disease, Vertex’s Casgevy (exagamglogene ... therapies at the 2024 Academy of Managed Care ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...